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The cDNA for strictosidine synthase, the enzyme catalyzing the stereospecific condensation of tryptamine with secologanin producing strictosidine, 
the key intermediate in indole alkaloid biosynthesis, has been expressed in an enzymatically active form in Escherichiu co/i. The cDNA trimmed 
of its 3’- and 5’-flanking regions was inserted into the vector pKK223-3 by addition of a synthetic adapter containing the ribosome binding site 
derived from the p-galactosidase gene. Strictosidine synthase activity (138 nkat ‘1 -i) could be measured in both whole bacteria and in bacterial 
protein extracts. Strictosidine synthase represents the first enzyme of plant secondary metabolism to be actively expressed in a microorganism. 
Strictosidine synthase; Indole alkaloid biosynthesis; Cloned enzyme expression; (Rauvolfia serpentinn, Escherichiu co/i) 
1. INTRODUCTION 
Strictosidine, the key intermediate leading to over 
1800 indole alkaloids, was initially identified as such 
more than 20 years ago [l]. Subsequent studies led to 
a discrepancy concerning the correct stereochemistry of 
the precursor [2,3] which was resolved as the 3a(S)- 
epimer only after the discovery of the enzyme which 
catalyzes the condensation of tryptamine and 
secologanin to form strictosidine (fig.1) [4,5]. The en- 
zyme, strictosidine synthase, from Rauvolfia serpen- 
tina has been purified to homogeneity and 
characterized [6]. In immobilized form, the enzyme 
[6,7] is extremely stable such that it is possible to pro- 
duce strictosidine in gram quantities with as little as 24 
nkat in a 10 x 50 mm column. The precursors, tryp- 
tamine and secologanin, are attainable commercially 
and through a simple isolation procedure, respectively 
[8]. The potential to produce known indole alkaloids 
through biomimetic syntheses or to develop potentially 
new drugs by modification of the alkaloidal glucoside 
[9] then depends only on the availability of the 
biocatalyst, strictosidine synthase. The cDNA for this 
enzyme from R. serpentina has recently been attained, 
found to contain an open reading frame of 1032 base 
pairs encoding 344 amino acids and the protein has 
been expressed in Escherichia coli [lo]. Expression of 
the active enzyme in a microorganism would lead to the 
unlimited amounts of catalyst required for production 
of strictosidine and for a thorough analysis of the reac- 
tion mechanism and regulation of this central enzyme 
in indole alkaloid metabolism. 
Reported here is the expression of enzymatically ac- 
tive strictosidine synthase in E. coli. 
2. MATERIALS AND METHODS 
2.1. Materials 
The cDNA clone for strictosidine synthase and the anti-strictos- 
idine synthase antibodies were obtained as previously described [lo]. 
Restriction enzymes, T4 DNA ligase and Exonuclease III were from 
Boehringer Mannheim, and the eukaryotic expression vector 
pKK223-3 was from Pharmacia. Sequenase was purchased from 
United States Biochemical Corp. 
2.2. Construction of expression vector 
The 3Xlanking region of the cDNA for strictosidine synthase clon- 
ed into the EcoRI restriction site in pUC18 was removed by digestion 
with PstI (in polylinker) and AvaI (unique site 84 base pairs 
downstream from the stop codon). The remainder of the region was 
digested to within 32 base pairs of the UAA codon with Exonuclease 
III, the ends filled in with Klenow polymerase and the vector cir- 
cularized and transformed into E. coli DH5. The plasmid DNA from 
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Fig.1. Condensation of tryptamine and secologanin catalyzed by 
strictosidine synthase to form the 3a(S)-glucoalkaloid, strictosidine. 
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this preparation was then digested with HindIII (in polylinker) and 
Bull (unique site immediately 3’ to the translational start codon) and 
the restriction fragment purified by agarose gel electrophoresis. The 
NindIII-Ba/I fragment was ligated into EcoRI-Hind111 restricted 
pKK223-3 together with a synthetic adapter containing a sequence 
derived from the ribosome binding site of the fl-galactosidase gene 
and the ATGG region which had been removed from the open 
reading frame of the strictosidine synthase cDNA through BulI diges- 
tion. This final construct (pKSS1) was introduced initially into E. coli 
DH5 and subsequently into E. coli SC935 for expression. 
2.3. Enzyme assay 
E. coli SC935 containing pKSS1 was grown in a modified Luria- 
Bertani medium composed of 2% Bacto Tryptone, 1% Bacto Yeast 
Extract, 1% NaCl, 5% glycerol with 100 pgg/ml ampicillin to an Asm 
of 12.0. Cells were collected by centrifugation (7000 x g,5 min, 4”C), 
washed with 100 mM NaCI, 10 mM Tris-HCI, 1 mM EDTA, pH 8.0, 
and resuspended in 4 ml of 20 mM potassium phosphate, pH 6.5, and 
either used directly for enzyme assays or were broken by sonication, 
centrifuged (3O.OCO x g, 20 min, 4°C) and the supernatant used for 
enzyme assays. The enzyme assay for strictosidine synthase was per- 
formed as previously described [I 11. 
2.4. immunological procedures 
E. co/i SC935 containing pKSS1 was grown in Luria-Bertani 
medium containing 100 /tg/ml ampicillin to an Asso of 2.0 at which 
time chloramphenicol was added to the growth medium to a final 
concentration of 100 pg/ml. A 30 $1 aliquot of cells was removed at 
0,lO and 40 min. after chlorampheniciol addition and immediately 
frozen at -80°C. Total bacteria1 protein was fractionated on an SDS- 
polyacrylamide gel (11070) and blotted onto nitrocellulose. Filters 
were treated with strictosidine synthase-specific antibodies and ‘*‘I- 
protein A as in [lo] with the following modification: the antibody 
was pretreated with a protein extract (1 mg/ml final protein concen- 
tration) of E. coli SC935 containing the empty vector pKK223-3 for 
30 min at room temperature prior to addition to the nitr~eilulose 
filters. This served to reduce background ue to cross reaction of the 
crude antisera with bacterial proteins. 
2.5. Structure elucidation of reaction product 
Strictosidine was produced by incubation (1 h, 37’C) of a solution 
containing 15 mM secologanin, 15 mM tryptamine, 100 mM 
potassium phosphate pH 6.5 and either whole bacteria (E. co/i SC935 
containing pKSS1) or a crude protein extract (representing 14 nkat 
enzyme) of this same bacterial strain obtained as described in 2.3. 
Bacteria were removed by centrifugation (7000 x g, 5 min, 4°C) and 
the reaction mixture lyophilized. Strictosidine was isolated from the 
methanol-soluble fraction by thin layer chromatography (TLC) on 
SIL G/UVts4 (Machery and Nagel) plates in solvent system I 
(acetone/methanol/diethylamine, 7:2:1) and acetylated [12]. The 
penta-acetate of the glucoalkaloid was purified by consecutive 
chromatography in the following 3 solvent systems: II 
(benzenelethylacetate, 2:l); III (ethylacetate/n-hexane 4:6); IV 
{benzene/acetone/petroleum ether, 5:2:3). The bacterially produced 
strictosidine was further characterized by derivatization to the lactam 
followed by acetylation according to [12]. 
2.6. General methods 
The oligonucleotides were synthesized with an Applied Biosystems 
380B DNA synthesizer. NMR measurements were made on a 360 
MHz Brucker Aspect 3000 NMR spectrometer. Supercoil DNA se- 
quencing was performed according to the dideoxy chain termination 
method of Sanger [13]. Protein determinations were as described by 
Bradford 1141. 
3. RESULTS 
3.1. Construction of expression vector 
The cDNA clone for strictosidine synthase from 
Rauvolfia serpent&a contained a 1032 base pair open 
reading frame together with 60 base pairs at the 5’ end 
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and 120 bases of 3’-flanking region [IO]. The cDNA, 
as originaIly subcloned into pUC18, out of frame with 
respect o the &galactosidase gene exhibited enzyme ac- 
tivity. In order to increase the total amount of enzyme 
produced in the bacterium, the cDNA was modified as 
follows. The 5’-flanking region of the cDNA clone 
(fig.2) was removed by digestion with Ban which 
recognized a unique restriction site immediately 3’ to 
the first ATG and then with EcoRI. The EcoRI/BaZI 
fragment was replaced by a synthetic oligodeox- 
ynucleotide adapter which contained the ribosome 
binding site sequence of the P-galactosidase gene 
together with the ATGG sequence of the reading frame 
which had been removed through Ball digestion. The 
3’-tanking region of the cDNA clone was digested 
with Exonuclease III to within 32 base pairs of the stop 
codon to remove the poly A tail and stabilize the 
messenger RNA. Ultimately, the trimmed cDNA and 
the adapter were ligated into EcoRI/HindIII digested 
pKK223-3 to form the expression vector pKSS1. 
3.2. Expression of active enzyme 
A series of vector constructs, bacterial strains and 
culture conditions were tested, the results of several of 
which are represented in table 1. In general, the expres- 
sion vector pKSS1 yielded a 2-fold increase in the 
amount of enzyme produced as compared to pUC18 
with the cDNA in the correct reading frame expressed 
as a ~-g~actosidase fusion protein (pUCl8-4~. Nor- 
thern blot analysis of RNA from bacteria containing 
either construct indicated that the messenger RNA 
transcribed from pKSS1 was more stable than that 
from pUC18-4 presumably due to the presence of the 
transcription terminator, rrnBT1Tz (data not shown). 
The ion -, htpr - E. coli strain SG935 accumulated 5 
times more enzyme than did E. coli DHS, suggesting 
that the cloned gene product is more stable in the pro- 
tease deficient strain. This stability was monitored in E. 
co/i SG935 with “251-protein A-treated immunoblots of 
bacterial protein extracts under conditions of protein 
synthesis followed by treatment with chloramphenicol. 
The eukaryotic protein was stable for at least 40 min 
(fig.3A) after the addition of chloramphenicol. It 
became apparent through this analysis that the 
bacterium was processing the cloned gene product. This 
same phenomemon was observed with the enzyme ex- 
pressed as a @-galactosidase fusion protein in pUC18 
(fig.3B). Enzyme assays performed at various time 
points after chloramphenicol addition indicated that 
the processing did not significantly affect the catalytic 
activity. 
After the establishment of the expression system, 
whole bacteria containing pKSS1 were tested for the 
capacity to condense secologanin and tryptamine to 
strictosidine. It was found that when E. cofi SG935 was 
either resuspended in potassium phosphate buffer, 
pH 6.5 or maintained in the growth medium, the addi- 
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Fig.2. Construction of the strictosidine synthase expression vector 
pKSS1. 
Table 1 
Catalytic activity of cloned strictosidine synthase in E. co/i 
Vector 
construct 
Activity 
(nkat. I-‘) 
Relative 
activity 
% Soluble 
protein 
pUCl8SSl.lO/DHS” 0.45 1 0.0002 
pKSSl/DHSb 1.93 4.3 0.0008 
pUC18-4/SG935’ 4.91 10.9 0.002 
pKSSl/SG935 (2)d 9.12 21.6 0.004 
pKSSlLSG935 (12)e 138’ 330 0.063 
a Construct represents the original cDNA with both the 5’- and 
3’-flanking regions subcloned out of frame with respect to the fl- 
galactosidase gene in pUC18 expressed in E. co/i DH5 grown to 
A590=2.0 
bE. coli DH5 containing pKSS1 grown to AJ~ = 2.0 
’ E. coli SG935 containing pUCl8-4 grown to As9,~=2.0 
dE. co/i SG935 containing pKSS1 grown to A590 = 2.0 
’ and grown to Am = 12.0. The percentage of soluble bacterial pro- 
tein was calculated based on a specific activity equivalent o that of 
the plant-produced enzyme 
f Equivalent o 7.9 fkat strictosidine synthase activity per IO6 bacteria 
and a production of 19.7 nkat. -’ per hour of culture time. Produc- 
tion of the enzyme in R. serpentine cell suspension culture is 1.0 
nkat . I-’ per hour of culture time [6]. 
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Fig.3. Autoradiogram of rZSI-protein A-treated immunoblot of total 
protein from E. coli SG935 containing (A) pKSS1 and (B) pUCl8-4 
@-galactosidase fusion protein). The time after the addition of 
chloramphenicol to the growth medium at which aliquots were 
removed for electrophoresis as indicated. (Arrow indicates position 
of bacterially-processed strictosidine synthase protein.) 
tion of equimolar (15 mM) concentrations of secol- 
oganin and tryptamine to the suspension resulted in the 
quantitative conversion of the precursors to strictos- 
idine. Analysis of the medium, soluble protein and 
membrane bound protein indicated that the enzyme 
was in a soluble form exclusively within the bacterium 
but the product, strictosidine, accumulated in the 
medium. 
3.3. Characterization of reaction product 
To produce sufficient quantities of the reaction pro- 
duct for verification of the structure and stereo- 
chemistry of the glucoalkaloid, equimolar concentra- 
tions of secologanin and tryptamine were added to 
either intact E. coli SG935 containing pKSS1 or to a 
protein extract of this strain. Within one hour, the tryp- 
tamine has been exhausted. When the reaction was per- 
formed with isotopically labeled tryptamine, only one 
product was formed in quantitative yield (Z?r 0.68 in 
TLC solvent I, superimposable with authentic stric- 
tosidine). The bacterially produced strictosidine was 
readily purified by TLC and either directly acetylated 
or first cyclized to the lactam, then acetylated. The ‘H- 
NMR spectrum of the penta-acetyl derivative was in 
every respect identical to that of authentic standard as 
was the ‘H-NMR spectrum of the purified tetra-acetate 
of strictosamide [12] (CDC13, (CH&Si, 360 MHz) 6 
2.07, 1.99, 1.88 (9H, s, OCOCH3) which unambiguous- 
ly contained the characteristic anomalous acetate signal 
at 6 1.22 (3H, s, OCOCH3) indicative exclusively of the 
3a(S)-epimer. 
4. DISCUSSION 
The cDNA clone for strictosidine synthase from 
Rauvolfia serpentina has been expressed in an en- 
zymatically active form in E. coli. This represents the 
first example of a gene of plant secondary metabolism 
which has been expressed in an active form in a 
bacterium. As such, it has opened a new field in the 
study of alkaloid metabolism and its biotechnological 
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applications. Virtually unlimited quantities of stric- REFERENCES 
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tosidine can now be readily and rapidly produced by in- 
tact, non-permeabilized bacteria. The system is 
superior to the plant R. serpentina in that on a time 
basis, 20 times more enzyme per liter is produced in the 
microbial culture than in the plant suspension culture 
[6]. In addition, strictosidine is not modified in any way 
by the bacterium, resulting in an accumulation of the 
genuine glucoalkaloid. Biomimetic synthesis of phar- 
macologically active indole alkoids starting from stric- 
tosidine and a detailed biochemical analysis of the reac- 
tion catalyzed by strictosidine synthase have now 
become more attainable. 
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